Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells-Reference-Cited by-同舟云学术

Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells

Published:2023-12 Issue: Volume:168 Page:115635
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Cammann Clemens,Kulla Jonas,Wiebusch Lüder,Walz Christian,Zhao Fang,Lowinus Theresa,Topfstedt Eylin,Mishra Neha,Henklein Petra,Bommhardt Ursula,Bossaller Lukas,Hagemeier Christian,Schadendorf Dirk,Schmidt Boris^ORCID,Paschen Annette,Seifert Ulrike^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference57 articles.

1. The era of checkpoint inhibition: lessons learned from melanoma;Paschen;Recent Results Cancer Res,2020

2. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma;Liu;Nat. Med,2019

3. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N. Engl. J. Med,2014

4. Randomized phase iii trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma;Dummer;J. Clin. Oncol.,2022

5. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – an evaluation of the multicenter prospective skin cancer registry ADOREG;Kreft;Eur. J. Cancer,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights into voltage-gated ion channels: Translational breakthroughs in medical oncology;Channels;2023-12-28